We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Oncorus, Inc., a clinical stage biopharmaceutical company developing next-gen viral immunotherapies for cancer, has signed a 15-year lease to build a state-of-the-art, 88,000 sq.-ft. GMP viral immunotherapy clinical manufacturing facility in Andover ...